Just been diving into the AI drug discovery space and found three companies worth keeping an eye on right now. The intersection of machine learning and pharmaceutical development is getting pretty interesting, and these firms are actually showing real progress rather than just hype.

First up is Schrödinger. They've been quietly working on this for years, way before AI became the buzzword it is today. What caught my attention is how they're playing both sides of the game - selling software licenses to other biotech companies while also running their own drug discovery pipeline. They've actually gotten two therapies to FDA approval already through collaborations with heavyweight pharma names like Eli Lilly and Bristol Myers Squibb. That's not nothing. The company's sitting on over half a billion in cash, which gives them real runway. Their stock had a strong run in 2023, and they've already shown they can turn a profit, which sets them apart from most AI drug discovery companies still burning through cash.

Then there's Recursion Pharmaceuticals. Their angle is pretty wild - they're basically industrializing drug discovery using AI and automation. They can run millions of wet lab experiments weekly through machine learning. The challenge is that most of their pipeline targets rare diseases, so even when they eventually get something to market, the revenue potential is limited. That said, they just landed a $50 million partnership with Nvidia and have collaborations with Roche and Bayer brewing. They're definitely a longer-term play, and you need patience with this one.

Exscientia is the third one. They're focused on AI-driven oncology therapies and just opened an automation lab in the UK. Their pipeline is pretty early stage though - everything's in phase 1 or 2 or earlier. They've got decent cash reserves, but the biggest risk here is that they're years away from any real revenue. That said, their focus on cancer drugs is smart, and having partners like Bristol Myers Squibb doesn't hurt.

If I had to pick which AI drug discovery companies have the best shot near term, Schrödinger looks like the safer bet since they've already proven the model works. Recursion could be solid for patient long-term investors willing to wait. Exscientia's the wildcard - highest risk but interesting upside if things click. The whole space is still early, but these three are among the few actually delivering results beyond just press releases.